Barrons.com51d agoneutral
Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger StoryGilead Sciences posts higher revenue as its market-leading HIV drug portfolio continues to drive growth.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
145last 24h
874last 7d
145● bullish (7d)
96● bearish (7d)
214publishers
24/7 Wall St.110d agoneutral
SpaceX IPO Could Create ‘The Biggest Short Squeeze’ of All Time on Index Funds. Here’s How That Happens.The phrase sounds almost impossible: a short squeeze involving index funds. After all, index funds are designed to be passive, rules-based buyers, not active traders caught on the wrong side of a position. Yet that is exactly the scenario Animal Spirits hosts Michael Batnick and Ben Carlson laid out on Episode 467, “The Biggest Short ... SpaceX IPO Could Create ‘The Biggest Short Squeeze’ of All Time on Index Funds. Here’s How That Happens.
Pharmaceutical Technology125d agoneutral
Gilead Sciences completes Tubulis acquisition for $5bnGilead acquired all outstanding equity of Tubulis for $3.15bn upfront, plus up to $1.85bn in milestone payments.
Reuters140d agobearish
Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitionsBy Deena Beasley LOS ANGELES, May 7 (Reuters) - Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said it now expects a loss for